The Cloning of CB1 — The Brain's Most Abundant Receptor and the Reason Cannabis Works
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
In 1990, a US government lab cloned the gene for the cannabinoid receptor (CB1), revealing it to be a G-protein-coupled receptor and the most abundant receptor of its kind in the mammalian brain — explaining why cannabis affects so many bodily functions.
By 1988, the evidence was overwhelming. Cannabinoids didn't just dissolve into cell membranes and cause chaos. They bound something specific — something saturable, stereoselective, coupled to G-proteins. A receptor. But nobody had the gene. Nobody could say what the protein looked like, how many amino acids it had, or where exactly its messenger RNA was expressed.
In Bethesda, Maryland, a laboratory at the National Institute of Mental Health was systematically cloning orphan receptors from rat brain tissue — receptors whose genes could be identified but whose function was unknown. One of them was about to become the most important receptor in cannabis science.
The Evidence Before the Gene
The pharmacological case for a cannabinoid receptor had been building for years.
In 1988, Allyn Howlett and William Devane at St. Louis University demonstrated that a synthetic cannabinoid (CP55940, developed by Pfizer) bound to specific sites in rat brain membranes with extraordinary precision. The binding was saturable — there were a finite number of sites, not infinite membrane surface. It was stereoselective — one mirror-image form of the molecule bound while its twin did not. And it was sensitive to pertussis toxin, which meant the binding site was coupled to Gi/o proteins — the same signaling family used by opioid and serotonin receptors.
This wasn't membrane disruption. This was a receptor.
In 1989, Miles Herkenham at the NIMH mapped where these binding sites were densest using autoradiography — essentially, radioactive cannabinoids photographing their own binding pattern across sliced rat brains. The map showed dense binding in the hippocampus, cerebellum, basal ganglia, and cortex. The shadow of the receptor was visible. Its gene was not.
Fishing for Orphans
Tom Bonner's lab at the NIMH was in the business of finding new G-protein-coupled receptors. GPCRs are the largest family of cell-surface receptors in the human genome — over 800 members — and in the late 1980s, many were still uncharacterized. Bonner's team used a systematic approach: screen rat brain cDNA libraries for sequences with homology to known GPCRs, clone the candidates, express them in cell lines, and figure out what they respond to.
Lisa Matsuda, the first author, performed the core cloning and expression work. The key test was pharmacological: when the expressed receptor was exposed to psychoactive cannabinoids like THC, it inhibited adenylate cyclase powerfully. When exposed to non-psychoactive cannabinoids, it barely responded. The receptor was selective. It was specific. It was the molecular target through which cannabis works.
472 Amino Acids
The paper was published August 9, 1990, in Nature — one of the most prestigious scientific journals in the world. Four pages.
472
amino acids make up the human CB1 receptor protein — a seven-transmembrane-domain G-protein-coupled receptor that turned out to be the most abundant GPCR in the mammalian brain.
By comparison, the mu-opioid receptor (which mediates morphine's effects) is 400 amino acids and far less abundant.
Matsuda et al. (1990), Nature; Zou & Kumar (2018), PMC5877694
What the paper reported:
- A novel GPCR, 7 transmembrane domains, coupled to Gi/o proteins
- Inhibits adenylate cyclase dose-dependently, stereoselectively
- Responds preferentially to psychoactive cannabinoids
- mRNA localized to hippocampus, cerebellum, basal ganglia, cortex — matching known binding sites
- 97-99% amino acid identity between rat, mouse, and human versions — this receptor is ancient and conserved
The gene was designated CNR1. The receptor became known as CB1.
The Most Abundant Receptor You've Never Heard Of
The real surprise came from distribution studies that followed. CB1 wasn't just present in the brain — it was dominant.
CB1 is the most abundant G-protein-coupled receptor in the mammalian brain — denser than receptors for serotonin, dopamine, opioids, or any other neurotransmitter system. This single fact explains the breadth of cannabis effects:
- Hippocampus (high density) → THC impairs short-term memory
- Cerebellum (high density) → THC disrupts coordination and balance
- Basal ganglia (high density) → THC alters movement and reward processing
- Cortex (moderate density) → THC changes perception and cognition
- Amygdala (moderate density) → THC can trigger anxiety or paranoia
- Hypothalamus (moderate density) → THC stimulates appetite (the munchies)
- Brainstem (very low density) → Cannabis doesn't stop breathing or heartbeat
That last point is clinically significant. Opioid receptors are dense in the brainstem, which is why opioid overdoses cause fatal respiratory depression. CB1 receptors are sparse there, which is a major reason cannabis has never caused a confirmed overdose death from respiratory failure.
Not Just a "Marijuana Receptor"
Myth vs. Reality
CB1 is the 'marijuana receptor' — it exists because of the cannabis plant.
CB1 evolved hundreds of millions of years before humans encountered cannabis. It exists for the endocannabinoid system — the body's own cannabinoid signaling network. THC works because it hijacks a receptor the brain built for its own molecules.
The Evidence
CB1 is found in virtually all vertebrates, including fish and reptiles that have no evolutionary exposure to cannabis. The endocannabinoid system predates the cannabis plant by hundreds of millions of years. The receptor's endogenous ligands — anandamide and 2-AG — were not discovered until 1992 and 1995, after the receptor itself was cloned.
McPartland et al. (2006); Zou & Kumar (2018), PMC5877694
And CB1 isn't confined to the brain. Subsequent research found it throughout the body:
- Gut — the enteric nervous system and intestinal mucosa, regulating motility and secretion
- Liver — low normally but dramatically upregulated in disease, contributing to insulin resistance and fibrosis
- Heart and blood vessels — upregulated in cardiovascular disease
- Peripheral nerves — dorsal root ganglia, trigeminal ganglion, regulating pain signaling
- Fat tissue — involved in metabolic regulation
- Immune cells — present on some white blood cells
Even within neurons, CB1 isn't limited to the cell surface. It's been found on mitochondria — the cell's energy factories — where it directly regulates cellular respiration. The receptor is as fundamental as it is ubiquitous.
CB1 and CB2 — Siblings, Not Twins
Three years after CB1 was cloned, Sean Munro at the MRC Laboratory of Molecular Biology in Cambridge identified a second cannabinoid receptor from an immune cell library.
The two receptors share less than half their amino acid sequence, evolved to serve different physiological roles, and are expressed in largely different tissue types. But both bind THC and endocannabinoids, and both belong to the GPCR superfamily. Together they form the receptor foundation of the endocannabinoid system.
What Knowing the Gene Made Possible
Cloning CB1 didn't just identify a protein. It handed researchers a toolkit: the ability to make knockout mice, design selective drugs, map the receptor's structure at atomic resolution, and understand exactly how cannabis interacts with the brain.
The Cautionary Tale of Rimonabant
Once you know a receptor's gene, you can design drugs against it. The pharmaceutical industry did exactly that — and the result was both a triumph and a disaster.
The lesson was profound. CB1 is not a peripheral metabolic switch you can flip without consequences. It's woven into the brain's fundamental architecture for processing reward, regulating mood, and managing stress. You can't simply turn it off.
Why This Matters for Cannabis Users
Understanding CB1 biology explains three things that every cannabis user experiences:
Tolerance: When THC floods CB1 receptors chronically, the brain responds by pulling receptors off the cell surface (internalization) and reducing their sensitivity (desensitization). Fewer functional CB1 receptors means you need more THC for the same effect.
Withdrawal: When you stop using cannabis, your brain has fewer CB1 receptors than normal — and the endocannabinoid system those receptors serve is temporarily impaired. This is why withdrawal produces anxiety, insomnia, irritability, and appetite loss — all functions CB1 regulates.
Recovery: CB1 receptors recover. Imaging studies show that receptor density returns to normal levels within approximately 2-4 weeks of abstinence. This is the biological basis for tolerance breaks — you're not just "resetting" subjectively, you're allowing your CB1 receptors to come back to the cell surface.
The receptor Matsuda's team cloned in 1990 is the same receptor your brain is adjusting every time you use cannabis. Knowing its gene made it possible to understand — at the molecular level — exactly what chronic use does and why recovery works.
Frequently Asked Questions
Cite this study
Matsuda, L A; Lolait, S J; Brownstein, M J; Young, A C; Bonner, T I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561-564. https://doi.org/10.1038/346561a0